

• Appln. No. 10/715,823
Amdt. dated October 11, 2005
Reply to Office action of April 8, 2005

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended). A method for the treatment of inflammatory arthritis (IA) in a human subject, comprising: orally administering to an individual in need of such treatment an effective amount of an active agent consisting of N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA;

wherein the effective amount is an amount which is ~~in a range between D_x and D_y ; D_x being an amount lower than D_{MAX} and D_y being an amount higher than D_{MAX} ; D_{MAX} being an amount that yields a maximal therapeutic effect; both D_x and D_y yield a therapeutic effect that is substantially less than that obtained at D_{MAX}~~ less than a daily dose of about 70 microgram/Kg.

2-4 (Cancelled)

5 (Original). A method of Claim 1, wherein the active agent is administered once a day at a dose of less than about 5 mg.

Appln. No. 10/715,823
Amdt. dated October 11, 2005
Reply to Office action of April 8, 2005

6 (Currently Amended). A method of Claim 1, wherein the active agent is administered twice a day at a dose of less than about 57 microgram/Kg each dose.

7 (Original). A method of Claim 1, wherein the active agent is administered twice a day at a dose of less than about 4 mg each dose.

8 (Currently Amended). A method for the treatment of inflammatory arthritis (IA) in a human ~~subject~~subject, comprising orally administering to an individual in need of such treatment an effective amount of N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (~~CL~~Cl-IB-MECA), wherein the effective amount is an amount which is the human equivalent of a murine dose of 0.001 mg/Kg to 0.4 mg/Kg administered once or twice per day.

9 (Currently Amended). A method according to Claim 78, wherein the effective amount is an amount within the range of about 0.14 to about 57 microgram/Kg.

10 (Currently Amended). A method according to Claim 78, wherein the effective amount is within the range of about 0.01 to 4 mg.

11 (Currently Amended). A method according to Claim 78, wherein the effective amount is an amount within the range of about 0.14 to about 28 microgram/Kg.

• Appln. No. 10/715,823
Amdt. dated October 11, 2005
Reply to Office action of April 8, 2005

12 (Currently Amended). A method according to Claim
78, wherein the effective amount is a dose within the range of
about 0.01 to 2 mg.

13 (Currently Amended). A method according to Claim
78, wherein the effective amount is an amount within the range
of about 1.4 to about 21 microgram/Kg.

14 (Currently Amended). A method according to Claim
78, wherein the effective amount is a dose within the range of
about 0.1 to 1.5 mg.

15-27 (Cancelled)

28 (Currently Amended). A pharmaceutical
composition for use in the treatment of a method according to
any one of claims 1 ~~to~~ and 5-14.